AI-generated analysis. Always verify with the original filing.
Verrica Pharmaceuticals Inc. filed an 8-K on March 11, 2026, disclosing results of operations under Item 2.02, with Exhibit 99.1 Press Release attached. The information under Item 2.02 and Exhibit 99.1 is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Event Type
Disclosure
Mandatory
Variant
8-K
, and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release, dated March 11, 2026 104 Cover Page Interactive Data File